AI-extracted from the 10-Q filed 2026-08-04 — Q2 2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Q2 net sales rose 13.6% to $1,741.0M, but net income fell to $241.4M as the effective tax rate jumped to 53.6% on a $188.2M valuation allowance.
Higher sales of the SAPIEN 3 Ultra RESILIA valve in the United States, Europe, and Japan
Surgical$284.1M+6.5% YoY
Higher sales of INSPIRIS RESILIA, MITRIS RESILIA, and KONECT RESILIA in the United States and Europe
Transcatheter Mitral and Tricuspid Therapies (TMTT)$198.6M+47.7% YoY
Higher sales of PASCAL, EVOQUE, and SAPIEN M3 systems in the United States and Europe
Largest Expense Items
Selling, general, and administrative expenses$561.2M
Higher headcount related expenses and commercial activities; currency added $6.0 million
Cost of sales$392.4M
Increased with sales growth; partially offset by lower manufacturing expenses
Research and development expenses$278.9M
Increased investments in implantable heart failure management and advanced technology innovation
Certain litigation expenses$6.3M
Legal proceedings, intellectual property litigation and tax litigation, down from $15.5 million
Margins: Gross profit rose to $1,348.6M on sales growth, but gross margin declined roughly 0.7 percentage points from foreign currency rate fluctuations, including hedge settlements, partly offset by lower manufacturing expenses.
Watch Items from the Filing
Effective tax rate was 53.6% versus 16.1% a year ago, chiefly a $188.2 million valuation allowance after California legislation limited research and development credit carryovers.
IRS Final NOPAs propose U.S. taxable income increases of $625.3M, $530.7M, and $683.6M for 2018-2020, with 40% transfer pricing penalties expected in Q3 2026.
Recorded a $40.0 million impairment in the quarter on a terminated VIE option agreement; year-to-date impairments total $163.6 million.
Japan segment net sales were $96.4 million, up only 1.1% year over year, versus 12.8% U.S. and 16.2% Europe growth.
No customer represented 10% or more of total net sales; company holds $2.9 billion cash and $1.5 billion remaining repurchase authorization.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Davis Leslie C.DirectorGrant or award · May 8, 2026
Congress trading in EW
17 transactions in EW reported by 10 members of Congress under the STOCK Act, most recent trade Nov 19, 2025. Reported transactions, not recommendations.
About Edwards Lifesciences Corp (EW): stock profile, AI score and financials
Edwards Lifesciences Corp (EW) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EW at 69.6/100 on a composite quality score built from its SEC filings, placing it at rank #240 of 2,925 stocks — the top 10% of the AI-ranked universe. EW scores in the top quartile across institutional flow (95.2), revenue scale (81.4), earnings quality (79.0). Shareholder dilution risk is elevated at 34.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Edwards Lifesciences Corp reports quarterly revenue of $1.7B, net income of $241.9M, an operating margin of 29.5%. Top institutional holders of EW by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. EW trades on the NYSE exchange and files with the SEC under CIK 1099800. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EW daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Edwards Lifesciences Corp directly from SEC EDGAR.